Dimensional Fund Advisors LP Buys 93,682 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Dimensional Fund Advisors LP increased its stake in Charles River Laboratories International, Inc. (NYSE:CRL) by 20.0% during the second quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 561,075 shares of the medical research company’s stock after purchasing an additional 93,682 shares during the quarter. Dimensional Fund Advisors LP owned approximately 1.09% of Charles River Laboratories International worth $115,912,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Tortoise Investment Management LLC raised its holdings in Charles River Laboratories International by 77.0% in the 2nd quarter. Tortoise Investment Management LLC now owns 131 shares of the medical research company’s stock worth $27,000 after purchasing an additional 57 shares during the period. Headlands Technologies LLC bought a new position in Charles River Laboratories International in the 1st quarter worth $41,000. Brown Brothers Harriman & Co. raised its holdings in Charles River Laboratories International by 76.0% in the 4th quarter. Brown Brothers Harriman & Co. now owns 220 shares of the medical research company’s stock worth $52,000 after purchasing an additional 95 shares during the period. Sunbelt Securities Inc. raised its holdings in Charles River Laboratories International by 1,072.7% in the 1st quarter. Sunbelt Securities Inc. now owns 258 shares of the medical research company’s stock worth $70,000 after purchasing an additional 236 shares during the period. Finally, Concord Wealth Partners raised its holdings in Charles River Laboratories International by 362.5% during the first quarter. Concord Wealth Partners now owns 259 shares of the medical research company’s stock valued at $70,000 after acquiring an additional 203 shares during the period. 98.91% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research firms have commented on CRL. JPMorgan Chase & Co. cut Charles River Laboratories International from an “overweight” rating to a “neutral” rating and decreased their price target for the company from $270.00 to $205.00 in a report on Thursday, August 8th. Mizuho began coverage on Charles River Laboratories International in a report on Friday, June 7th. They set a “neutral” rating and a $235.00 price target on the stock. TD Cowen decreased their price target on Charles River Laboratories International from $228.00 to $203.00 and set a “hold” rating on the stock in a report on Monday, August 12th. UBS Group decreased their price target on Charles River Laboratories International from $290.00 to $240.00 and set a “buy” rating on the stock in a report on Thursday, August 8th. Finally, Argus reissued a “hold” rating on shares of Charles River Laboratories International in a report on Friday, June 28th. Ten investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, Charles River Laboratories International has a consensus rating of “Hold” and a consensus target price of $227.55.

Charles River Laboratories International Trading Down 1.0 %

CRL opened at $203.83 on Tuesday. The firm has a market cap of $10.50 billion, a P/E ratio of 23.98, a P/E/G ratio of 3.89 and a beta of 1.36. Charles River Laboratories International, Inc. has a 12 month low of $161.65 and a 12 month high of $275.00. The company has a current ratio of 1.58, a quick ratio of 1.21 and a debt-to-equity ratio of 0.65. The stock has a 50-day moving average of $209.09 and a 200 day moving average of $223.05.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings results on Wednesday, August 7th. The medical research company reported $2.80 EPS for the quarter, topping the consensus estimate of $2.39 by $0.41. The company had revenue of $1.03 billion during the quarter, compared to analyst estimates of $1.03 billion. Charles River Laboratories International had a return on equity of 14.96% and a net margin of 10.83%. As a group, research analysts forecast that Charles River Laboratories International, Inc. will post 10.01 EPS for the current year.

Charles River Laboratories International declared that its Board of Directors has initiated a stock buyback plan on Wednesday, August 7th that allows the company to buyback $1.00 billion in shares. This buyback authorization allows the medical research company to reacquire up to 9.6% of its stock through open market purchases. Stock buyback plans are usually a sign that the company’s board of directors believes its shares are undervalued.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).